Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Sermorelin

GHRH (1-29), GRF 1-29 NH2, Sermorelin acetate

Quick Stats
Studies 223
Trials 41
Completed OBSERVATIONAL NCT02507245

Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD)

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The aim of this study is to assess the developmental patterns of lung function in children affected by growth hormone deficiency after one year of GH therapy.The assessment by specific questionnaires of quality of life and of parental stress index.Parameters will be evaluated at the time of the diagnosis and after 12 months of GH therapy.

Detailed Description

Observational longitudinal study in children affected by idiopathic growth hormone deficiency (GHD): lung function parameters assessment; quality of life assessment; stress parenting assessment (Pneumo GHD). The aim of this study is to assess the developmental patterns of lung function in children affected by growth hormone deficiency after one year of GH therapy.The assessment by specific questionnaires of quality of life and of parental stress index.Parameters will be evaluated at the time of the diagnosis and after 12 months of GH therapy.

Interventions

Name: Growth Hormone-Releasing Hormone
Type: DRUG
Description: From Baseline Visit (T0) to 6th Month Visit 0,025 mg/kg Growth Hormone/die. From 6th Month Visit to 12th Month Visit 0,030 mg/Kg Growth Hormone/die.

Primary Outcomes

Measure: Assessment of the developmental patterns of lung function before and after GH by spirometry
TimeFrame: 1 year
Description: Assessment of lung function before and after administration of GH in children with growth hormone deficiency by spirometry

Trial Information

NCT ID

NCT02507245

Status

Completed

Study Type

OBSERVATIONAL

Sponsor

Stefania La Grutta, MD

Last Updated

December 15, 2025

Related Peptides